Targeting EZH2 may also be an effective strategy to overcome oxaliplatin resistance, since EZH2 was shown to promote oxaliplatin resistance in CRC cells, while EZH2 inhibitor suppressed tumor growth and sensitized CRC cells to oxaliplatin [172,173]. Here, EZH2 is linked to colorectal carcinoma.